SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs guidance that topline results from its Phase 3 REGAL trial of GPS in AML are expected this month, following the trials 80th event, has focused attention on the upcoming readout and coincided with a sharp after-hours move. Bulls are anticipating a successful result and discussing a possible short squeeze, while others caution that the data remain unreleased and speculation about a leak is unconfirmed.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,281. The last known price of Bitcoin is 71,086.72423286 USD and is down -3.89 over the last 24 hours. It is currently trading on 12779 active market(s) with $28,515,435,687.36 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins steep selloff and break below a closely watched support area dominate the discussion, with traders pointing to leveraged liquidations and broader risk-off selling. The community is split between expecting further downside and treating the drop as an oversold buying opportunity.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

A widespread Microsoft 365 outage disrupting Outlook, Teams, Copilot and other services is dominating discussion, with users describing work interruptions and traders questioning the hit to reliability and reputation. Some speculate about a cyberattack, but that remains unconfirmed; others are surprised the shares held relatively steady despite the disruption.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels FDA discussions over assay refinement have pushed the planned prostate-cancer BLA filing to mid-2027, prompting a sharp selloff and concern about the longer regulatory timeline. Traders disagree on whether this is a fixable manufacturing-and-testing delay that leaves the clinical data intact or a sign of broader execution problems; criticism of management and trust has intensified, while some investors remain confident in the science.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Ciscos quarterly earnings beat and raised outlook, driven by demand for AI-data-center networking, are the main focus. Traders see potential in a longer-term networking cycle but are frustrated by the muted, volatile share reaction and debate margin pressure, backlog trends, and whether AI orders will translate into durable revenue.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is under pressure after its Q3 report paired strong growth with a 2026 revenue outlook at the low end of its range, capacity delays, and sharply higher planned capital spending. Traders are split between those emphasizing AI demand and customer prepayments and those worried about execution, financing needs, and when the added capacity will generate revenue.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Anthropics reported confidential IPO filing has renewed attention on Zooms early investment in the AI company, with traders debating how much value the stake could add; bullish posts also point to Zooms enterprise and AI momentum, while skeptics question whether that offsets modest core growth and competition.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holdings Q3 earnings are driving attention: traders are weighing a reported beat and higher gross-margin outlook against softer direct-to-consumer growth and full-year guidance that was reiterated. Some see the selloff as a buying opportunity, while others question the quality of the beat because tariff refunds boosted reported margins.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell is caught in a volatile AI-hardware and data-center selloff, with traders pointing to Intels warning on PC demand and broader concerns about capex financing, server margins, and uncertainty around data-center expansion. Bulls see the drop as an overreaction and cite continued AI-server demand, while bears argue that thin-margin sales to debt-funded customers make that demand vulnerable.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

RUMs quarterly resultsrecord revenue growth and its first positive adjusted EBITDA, driven largely by Quake AIs GPU-cloud businesshave focused attention on its shift toward AI infrastructure. Bulls point to strong demand and high short interest, while skeptics question the cash and financing needed for the Maysville data-center expansion and whether it can be delivered on schedule.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

Natera, Inc. (Nasdaq:NTRA), a global leader in cell-free DNA and precision medicine, today announced that it has entered into a clinical collaboration agreement with Incyte (Nasdaq:INCY) for a new phase II study in colorectal cancer (CRC). The trial will evaluate INCA33890, Incytes investigational...

$1000 Invested In Incyte 20 Years Ago Would Be Worth This Much Today

Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.34% on an annualized basis producing an average annual return of 17.11%. Currently, Incyte has a market capitalization of $25.04 billion.read more...

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story

Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings Story Stocks Surged Across the Board Today, and Biotech Brought Its Own Earnings StoryPR NewswireNEW YORK, Nov. 4, 2026 NEW YORK, Nov. 4, 2026 /PRNewswire/ --Fly on Wall Street News Commentary- Wall Street's major indexes...

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to be held December 12 15, 2026, in New Orleans. Our ASH presentations...

Incyte to Present at Upcoming Investor Conferences

Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Wolfe Research Healthcare Conference on Tuesday, November 10, 2026 at 10:00 am (EST) Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 9:00 am (GMT...

This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR's target increased to $1,700.read more...

Incyte (INCY) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

INCY Q3 Loss Narrower Than Expected, Sales Beat, FY'26 View Raised

Incyte's Q3 2026 revenues beat estimates as strong product demand lifts sales 14%, prompting higher 2026 guidance despite acquisition-driven losses.

Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Incyte (INCY) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Incyte (INCY) Reports Q3 Loss, Beats Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of +9.77% and +5.06%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

• Reported GAAP EPS of -$3.60 down -259.29% YoY
• Reported revenue of $1.56B up 14.00% YoY
• Incyte raised full-year 2026 net sales guidance to $5.21B, Opzelura to $1.1B, and Hematology and Oncology to $890M, while reaffirming guidance for all other categories.

Incyte reported a Q3 2026 GAAP net loss and diluted EPS loss; R&D expenses increased, primarily driven by Vegas one-time IPR&D charge; Phase 3 ovarian cancer study enrollment was discontinued.

Incytes Q3 net sales increased 14%, with Opzelura and Hematology and Oncology sales increasing; Phase 1 oncology data supported further development, and EU approval represented Opzeluras second approved indication.

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded on April 8, 1991 and is headquartered in Wilmington, DE.

Incyte Corp.

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating.</li><li>RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.&nbsp;</li><li>BTIG said VS-7375 could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.</li></ul> Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company’s experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma.On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effectsVerastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end.<h2 class="st-heading-2">Wall Street Weighs In On VSTM</h2>Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class.RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class.<h2 class="st-heading-2">CEO Change And Capital Raising</h2>Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15.The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him.<h2 class="st-heading-2">How Did VSTM Retail Traders React?</h2>On Stocktwits, retail sentiment around VSTM stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.“The more I watch it, the more constructive it looks,” a Stocktwits user wrote about the stock.<stembedurl>https://stocktwits.com/topstockalerts/message/666627602</stembedurl>Another user drew a parallel between VSTM’s current rally and Iovance Biotherapeutics Inc (IOVA) stock’s rally last month, which lasted for several days.<stembedurl>https://stocktwits.com/Always_neutral/message/666623781</stembedurl><a class="mention" data-mention="$VSTM" data-symbol-id="VSTM" href="https://stocktwits.com/symbol/VSTM" target="_blank">VSTM stock</a> has gained 2o% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-hits-fresh-52-week-highs-as-goldman-raises-target-ahead-of-melanoma-data/cZxh3NsRBrS">MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 

Revolution Medicines Inc

Verastem Inc

Nvidia ($NVDA) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Stocktwits

) is moving lower after Jensen Huang resigned as CEO. Are you buying the dip?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$1.90	--	--	N/A
Q3 '26	-$3.93	-$3.60	8.49%	BEAT
Q2 '26	$2.20	$3.09	40.72%	BEAT
Q1 '26	$1.32	$1.81	37.56%	BEAT
Q4 '25	$1.91	$1.80	-5.53%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

INCY Earnings

Latest Earnings Results: Q3 '26

Historical Earnings